Fiduciary Group LLC Purchases 31,479 Shares of Pfizer Inc. (NYSE:PFE)

Fiduciary Group LLC increased its position in Pfizer Inc. (NYSE:PFE) by 36.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 117,669 shares of the biopharmaceutical company’s stock after acquiring an additional 31,479 shares during the period. Fiduciary Group LLC’s holdings in Pfizer were worth $3,122,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Teacher Retirement System of Texas increased its stake in shares of Pfizer by 93.3% in the 4th quarter. Teacher Retirement System of Texas now owns 1,969,261 shares of the biopharmaceutical company’s stock worth $52,244,000 after purchasing an additional 950,358 shares in the last quarter. Royal London Asset Management Ltd. increased its stake in shares of Pfizer by 2.8% in the 4th quarter. Royal London Asset Management Ltd. now owns 2,461,076 shares of the biopharmaceutical company’s stock worth $65,292,000 after purchasing an additional 67,788 shares in the last quarter. Credit Capital Investments LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $260,000. Kazazian Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $2,077,000. Finally, Generali Investments Management Co LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $656,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $26.18 on Thursday. The company has a market capitalization of $148.35 billion, a price-to-earnings ratio of 18.57, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm’s 50-day moving average is $26.19 and its 200 day moving average is $27.08. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.